Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 6/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 6/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 5/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14725553 | 0.86 | CYP17A1 (0.39) | — | |
| SCHEMBL14715962 | 0.86 | HPGD (0.49) | NPC1RAB9AKMT2AMEN1HPGD | |
| SCHEMBL14716072 | 0.85 | KMT2A (0.46) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14716095 | 0.81 | ALDH1A1 (0.37) | ALDH1A1NPC1RAB9AKMT2AHDAC3 | |
| SCHEMBL28177217 | 0.81 | ALDH1A1 (0.41) | ALDH1A1NPC1RAB9AKMT2AKCNQ3 | |
| SCHEMBL14716086 | 0.80 | BRAF (0.51) | — | |
| SCHEMBL14757434 | 0.78 | NPC1 (0.32) | ALDH1A1NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL27982016 | 0.76 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL28140582 | 0.76 | ALDH1A1 (0.36) | ALDH1A1NPC1RAB9AKMT2AKCNQ3 | |
| SCHEMBL14829793 | 0.75 | HSD17B1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170340630-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9572808-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2747767-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | ALDH1A1 3012/4885NPC1 4412/4885RAB9A 1846/4885 |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, BRAF, CHEK1 | ALDH1A1 3012/4885NPC1 4412/4885RAB9A 1846/4885 |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | ALDH1A1 3012/4885NPC1 4412/4885RAB9A 1846/4885 |
| US-20170340630-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | ALDH1A1 3012/4885NPC1 4412/4885RAB9A 1846/4885 |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, CHEK1, CHEK2 | ALDH1A1 3330/4885NPC1 4671/4885RAB9A 2163/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | ALDH1A1 2001/4885NPC1 2126/4885RAB9A 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.